Every 8-K that Vertex Pharmaceuticals Inc (VRTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow VRTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full VRTX filings page.
VERTEX PHARMACEUTICALS INC / MA (VRTX) appointed Jonathan Poole as Executive Vice President and Chief Financial Officer, effective January 1, 2027, while Charles F. Wagner, Jr. will remain Executive Vice President and Chief Operating Officer. Poole has served as Senior Vice President, Finance at Vertex since March 2020 and previously held CFO roles at several biotechnology companies.
Under his new employment agreement, Poole will receive a $750,000 base salary and a target annual bonus of 90% of base salary. If terminated without cause or he resigns for good reason, he is entitled to cash severance equal to 100% of base salary and target bonus, plus any earned but unpaid prior-year bonus, subject to a release. A separate change of control agreement provides for similar cash benefits, a pro‑rated target bonus, payment of other earned incentives, and full vesting of outstanding equity awards upon qualifying terminations around a change of control, plus up to 12 months of Company-paid medical, dental, and life insurance premiums if COBRA coverage is elected.
Vertex Pharmaceuticals reported Q2 2026 revenue of $3.33 billion, up 12% year over year, driven by cystic fibrosis products and growing contributions from CASGEVY and JOURNAVX. GAAP net income was $1.10 billion (diluted EPS $4.31); non-GAAP net income was $1.21 billion (EPS $4.73).
Cash, cash equivalents and marketable securities totaled $13.6 billion as of June 30, 2026, reflecting strong operating cash flow partially offset by share repurchases. The company raised full-year 2026 revenue guidance to $13.1–$13.2 billion, embedding expectations for $0.5 billion or more of non-CF product revenue.
Vertex highlighted rapid uptake of CASGEVY and JOURNAVX, an FDA PDUFA date of November 30, 2026 for IgAN drug povetacicept, and an agreement to acquire Crinetics Pharmaceuticals for about $10.0 billion, adding a rare endocrine disease portfolio.
Vertex Pharmaceuticals plans to acquire Crinetics Pharmaceuticals in an all-cash deal at $85.00 per share, implying a $10.0 billion equity value, or $8.8 billion net of cash. Crinetics will become a wholly owned subsidiary following the merger, which is expected to close in the third quarter of 2026, subject to shareholder and regulatory approvals.
Vertex expects to finance the transaction with cash on hand and a $4.5 billion unsecured 364‑day bridge loan facility. Management highlights the commercialized acromegaly drug PALSONIFY and late‑stage atumelnant for congenital adrenal hyperplasia as key strategic assets, targeting more than $5 billion in potential annual revenue and accretion to non‑GAAP operating income in 2029.
Vertex Pharmaceuticals held its annual shareholder meeting on May 13, 2026, where investors voted on board, compensation, auditor and governance matters. Shareholders elected ten directors, including Reshma Kewalramani and Jeffrey Leiden, each receiving over 209 million votes in favor.
Investors also approved the 2026 Stock and Option Plan, replacing the 2013 plan, with 216,097,268 votes for and 6,523,460 against. They ratified Ernst & Young LLP as independent auditor for the year ending December 31, 2026, with 223,514,070 votes for. On an advisory basis, shareholders backed the 2025 executive compensation program, and they passed a shareholder proposal granting the right to act by written consent.
Vertex Pharmaceuticals reported strong first quarter 2026 results, with total revenue rising 8% to $2.99 billion versus the first quarter of 2025. Growth was driven by cystic fibrosis therapies, especially ALYFTREK, and increasing contributions from CASGEVY and JOURNAVX.
GAAP net income increased to $1.03 billion from $646.3 million, helped by higher product revenues and the absence of last year’s intangible asset impairment charge. Non-GAAP net income rose to $1.15 billion. Vertex ended March 31, 2026 with $13.0 billion in cash, cash equivalents, and marketable securities and reaffirmed full-year 2026 revenue guidance of $12.95–$13.1 billion, including at least $0.5 billion from non-CF products.
Vertex Pharmaceuticals disclosed that director Suketu Upadhyay has decided not to stand for re-election at the company’s 2026 annual meeting of shareholders. He was recently named the forthcoming Chief Financial Officer of Incyte Corporation and cited scheduling conflicts with this new role.
Upadhyay will continue serving on the board until the 2026 annual meeting. The company stated that his decision did not involve any disagreement regarding its operations, policies, or practices. Following his departure, the board intends to reduce its size to ten members and the existing proxy materials are deemed amended to remove him from the slate of nominees, while all other nominees and previously submitted votes remain in effect.
Vertex Pharmaceuticals has completed submission of a rolling Biologics License Application to the FDA for povetacicept, seeking potential accelerated approval to treat immunoglobulin A nephropathy in adults. Vertex used a priority review voucher and therefore expects the FDA’s review to be expedited to six months from acceptance versus the typical ten-month review.
Vertex Pharmaceuticals reported strong growth for 2025, with total revenue of $12.0 billion, up 9% from 2024, and fourth quarter revenue of $3.19 billion, up 10%. Growth was driven by cystic fibrosis (CF) therapies and new products ALYFTREK, CASGEVY and JOURNAVX.
GAAP net income for 2025 was $3.95 billion, compared to a GAAP net loss of $(535.6) million in 2024, which was impacted by acquisition-related R&D. Non-GAAP net income rose to $4.75 billion from $110.6 million. Cash, cash equivalents and marketable securities reached $12.3 billion at year-end.
For 2026, the company guides to total revenue of $12.95–$13.1 billion, including $0.5 billion or more from non-CF products, and plans continued heavy investment in R&D and SG&A while advancing a broad mid- and late-stage pipeline across CF, gene editing, kidney disease, pain, autoimmune and diabetes programs.
Vertex Pharmaceuticals Incorporated filed a current report to note that it has released its latest quarterly and year-to-date financial results. On November 3, 2025, the company issued a press release reporting consolidated financial results for the three and nine months ended September 30, 2025. That press release is furnished as Exhibit 99.1 to this report and is incorporated by reference, but is not treated as "filed" for liability purposes under the Exchange Act.